190 related articles for article (PubMed ID: 6527953)
1. Recall of UVB-induced erythema in breast cancer patient receiving multiple drug chemotherapy.
Andersen KE; Lindskov R
Photodermatol; 1984 Jun; 1(3):129-32. PubMed ID: 6527953
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
5. A comparison of patient-reported side effects among three chemotherapy regimens for breast cancer.
Greene D; Nail LM; Fieler VK; Dudgeon D; Jones LS
Cancer Pract; 1994; 2(1):57-62. PubMed ID: 8055007
[TBL] [Abstract][Full Text] [Related]
6. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
7. [Side effects of combined antineoplastic chemotherapy on hemostasis in patients with breast cancer].
Pinto Pedrazzi AH; de Souza AM
Rev Fac Farm Odontol Ribeiro Preto; 1982; 19(1):29-41. PubMed ID: 6964932
[No Abstract] [Full Text] [Related]
8. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Hurria A; Brogan K; Panageas KS; Pearce C; Norton L; Jakubowski A; Zauderer M; Howard J; Hudis C
Breast Cancer Res Treat; 2005 Jul; 92(2):151-6. PubMed ID: 15986124
[TBL] [Abstract][Full Text] [Related]
9. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
[TBL] [Abstract][Full Text] [Related]
10. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
Domaradzka-Woźniak A; Wojtacki J; Dziewulska-Bokiniec A
Przegl Lek; 1994; 51(5):203-5. PubMed ID: 7938648
[TBL] [Abstract][Full Text] [Related]
11. [Prognostication of hematotoxicity for radio- and chemotherapy in patients with breast cancer].
Ivanov SD; Iamshanov VA; Korytova LI; Khazova TV; Arzumanov AS
Vopr Onkol; 2003; 49(5):601-7. PubMed ID: 14682132
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
13. Eosinophilic pustular folliculitis induced by chemotherapy.
Laing ME; Laing TA; Mulligan NJ; Keane FM
J Am Acad Dermatol; 2006 Apr; 54(4):729-30. PubMed ID: 16546603
[No Abstract] [Full Text] [Related]
14. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
Semiglasov VF; Stepula VV; Dudov A; Lehmacher W; Mengs U
Anticancer Res; 2004; 24(2C):1293-302. PubMed ID: 15154663
[TBL] [Abstract][Full Text] [Related]
15. [Results of a study on fatigue in breast cancer patients receiving adjuvant chemotherapy: the first four days after treatment are the worst].
de Jong N; Kester AD; Schouten HC; Abu-Saad HH; Courtens AM
Pflege Z; 2007 Nov; 60(11):620-5. PubMed ID: 18062627
[TBL] [Abstract][Full Text] [Related]
16. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil].
Ruffert K
Zentralbl Chir; 1998; 123 Suppl 5():156-8. PubMed ID: 10063603
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced acral erythema in a pediatric patient with acute monoblastic leukemia.
Demircioğlu F; Oren H; Yilmaz S; Arslansoyu S; Eren S; Irken G
Pediatr Hematol Oncol; 2008; 25(3):211-5. PubMed ID: 18432504
[TBL] [Abstract][Full Text] [Related]
18. LED photoprevention: reduced MED response following multiple LED exposures.
Barolet D; Boucher A
Lasers Surg Med; 2008 Feb; 40(2):106-12. PubMed ID: 18306161
[TBL] [Abstract][Full Text] [Related]
19. Potential risk of a common hereditary thrombophilia and adjuvant chemotherapy for low-stage breast cancer.
Ely SF
J Clin Oncol; 2005 Jun; 23(18):4242-3. PubMed ID: 15961781
[No Abstract] [Full Text] [Related]
20. Calling attention to radiation recall reactions. Simultaneous occurrence of a Recall Dermatitis after CMF application in two separate sites irradiated 10 years apart.
Partl R; Richtig E; Kapp KS
Acta Oncol; 2012 Jul; 51(6):809-11. PubMed ID: 22175251
[No Abstract] [Full Text] [Related]
[Next] [New Search]
